 Immuron Limited ASX: IMC; NASDAQ: IMRN, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to provide shareholders with an update on the companys research collaboration with the Naval Medical Research Center NMRC to develop and clinically evaluate a new therapeutic against campylobacter and ETEC E-Coli. The NMRC recently requested a Pre-IND meeting with the U.S. Food and Drug administration FDA regarding its new investigational drug which the company is developing to treat moderate to severe campylobacteriosis and ETEC infections. 